**Name of Journal: *World Journal of Clinical Cases***

**ESPS Manuscript NO: 26035**

**Manuscript Type: CASE REPORT**

**Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography evaluation of subcutaneous panniculitis-like T cell lymphoma and treatment response**

Gorodetskiy VR *et al*. FDG PET/CT in SPTCL patients

**Vadim R Gorodetskiy, Olga V Mukhortova, Irakli P Aslanidis, Wolfram Klapper,Natalya A Probatova**

**Vadim R Gorodetskiy,** Department of Intensive Methods of Therapy, V.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, 115522 Moscow, Russia

**Olga V Mukhortova**, **Irakli P Aslanidis,** Department of Nuclear Diagnostics, Bakoulev Scientific Center for Cardiovascular Surgery, 121552 Moscow, Russia

**Wolfram Klapper,** Department of Pathology, Hematopathology Section and Lymph Node Registry, Christian-Albrecht University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany

**Natalya A Probatova,** Department of Pathology, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, 115478 Moscow, Russia

**Author contributions:** Gorodetskiy VRdesigned the report, analyzed the data and wrote the paper; Mukhortova OV and Aslanidis IP performed the FDG PET/CT;Klapper W and Probatova NA performed the histological and immunohistochemical studies.

**Institutional review board statement:** The study was reviewed and approved by the Institutional Review Board of the V.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences.

**Informed consent statement:** All study participants provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interests regarding the publication of this study.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to: Vadim R Gorodetskiy**, **MD, PhD,** Department of Intensive Methods of Therapy, V.A. Nasonova Research Institute of Rheumatology, Russian Academy of Medical Sciences, Kashirskoye Shosse 34A, 115522 Moscow, Russia. gorodetskiyblood@mail.ru

**Telephone:** +7-916-5178192

**Fax:** +7-499-6144468

**Received:** March 28, 2016

**Peer-review started:** March 28, 2016

**First decision:** June 16, 2016

**Revised:** June 22, 2016

**Accepted:** July 11, 2016

**Article in press:**

**Published online:**

**Abstract**

Subcutaneous panniculitis-like T cell lymphoma (SPTCL) is a very rare variant of non-Hodgkin’s lymphoma. Currently, there is no standard imaging methodfor staging of SPTCL nor for assessment of treatment response. Here, we describe our use of fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for staging and monitoring of treatment response in 3 cases of SPTCL. Primary staging by PET/CT showed that all 3 patients had multiple foci in the subcutaneous fat tissue, with SUVmax from 10.5 to 14.6. Involvement of intra-abdominal fat with high SUVmax was identified in 2 of the patients. Use of the triple drug regimen of gemcitabine, cisplatin and methylprednisolone (commonly known as “GEM-P”) as first-line therapyorsecond-line therapyfacilitatedcomplete metabolic response for all 3 cases. FDG PET/CT provides valuable information for staging and monitoring of treatment response and can reveal occult involvement of the intra-abdominal visceral fat. High FDG uptake on pre-treatment PET can identify patients with aggressive disease and help in selection of first-line therapy.

**Key words:** Subcutaneous panniculitis-like T cell lymphoma; Positron emission tomography; Staging; Treatment; Non-Hodgkin’s lymphoma

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** We used fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for staging and monitoring of treatment response in 3 cases of subcutaneous panniculitis-like T cell lymphoma (SPTCL), a very rare variant of non-Hodgkin’s lymphoma. FDG PET/CT provided valuable information for SPTCL staging and monitoring of treatment response in the patients. It can reveal occult involvement of the intra-abdominal visceral fat and identify patients with aggressive SPTCL disease.

Gorodetskiy VR, Mukhortova OV, Aslanidis IP, Klapper W,Probatova NA. Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography evaluation of subcutaneous panniculitis-like T cell lymphoma and treatment response. *World J Clin Cases* 2016; In press

**INTRODUCTION**

Subcutaneous panniculitis-like T cell lymphoma (SPTCL) was first defined as a clinical entity in 1991, and described as a cytotoxic T cell lymphoma that preferentially infiltrates the subcutaneous tissue[1].Patients present with multiple subcutaneous nodules, usually exclusively, with no other involved sites[2-5]. The original description of SPTCL was further refined in 2008 by the World Health Organization, which restricted the classification to exclude γδT cell lymphoma[2]. To date, SPTCL remains a very rare variant ofnon-Hodgkin’s lymphoma, and the hematologist faces several unresolved issues in the management of patients with SPTCL. The best imaging methodfor staging of SPTCL and assessment of response to treatment in patients is controversial.

We report here 3 cases of SPTCL that were examined by positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) combined with computed tomography (CT) in order to determine their disease stage and to monitor their treatment response.

**CASE REPORT**

All 3 cases of SPTCL were diagnosed in the V.A. Nasonova Research Institute of Rheumatology (Moscow, Russia). On admission to the Institute, each patient underwent laboratory testing for complete blood count, urinalysis, blood chemistry and immunological analysis, the latter of which included measurement of antinuclear antibodies by indirect immunofluorescence test and of antibody titer for double-stranded DNA, Sm, anti-Ro and anti-La. In addition, histological and cytological examination of the bone marrow was performed. Formalin-fixed and paraffin-embedded skin biopsy specimens were also reviewed by 2 pathologists working independently (Wolfram Klapper andNatalya A Probatova), which was followed by immunohistochemical staining and molecular analyses. The immunohistochemical study of paraffin-embedded sections was performed using a wide panel of antibodies, including CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD20, CD56, CD68, CD138, VS38c, Ki67 (proliferation marker, expressed as %), granzyme B, TIA1, perforin, F1 and TdT. The T cell receptor (TCR) C gamma M1-antibody (gamma 3.20; Pierce Biotechnology, Rockford, IL, United States) was used for staining of TCRγ.

Determination of T cell clonality by investigating rearrangements of the genes encoding the gamma, beta and delta chains of TCRs was carried out on paraffin-embedded tissue blocks using the polymerase chain reaction (PCR) followed by fragment analysis as described previously[6,7].

All patients underwent whole-body FDG PET/CT, with calculation of the maximum standardized FDG accumulation in pathological foci (standard uptake value, SUVmax). FDG PET/CT studies were performed before treatment, during the treatment, and 1 mo after completion of chemotherapy.

The complete resolution of FDG uptake at sites of initial disease and the absence of new uptake areas were considered to indicate complete metabolic response (CMR), and were treated as a complete remission of lymphoma regardless of presence of nodules in the subcutaneous tissue found upon physical examination or of residual tumor signs found on CT.

***Histological, immunohistochemical and molecular features***

All 3 cases showed the characteristic panniculitis-like infiltration with obvious rimming of subcutaneous fat cells. The observed atypical CD8-positive lymphoma cells were small and medium-sized. Tumor infiltration did not affect the dermis and epidermis. The lymphoma cells were positive for TCRβ, CD3 and CD8, and expressed the cytotoxic markers TIA1, granzyme B and perforin. Proliferation rate of the neoplastic T cells was 50%-70% (as indicated by Ki-67) for all 3 cases. T cell clonality was confirmed in case 1, which showed incomplete (Dβ-Jβ) clonal rearrangement of the TCR β chain, and case 3, which showed complete clonal rearrangement of the TCR β and γ chains.

***Clinical features and results of FDG PET/CT***

Table 1 shows the clinical features of the 3 patients (2 females and 1 male). Two patients had autoimmune disorders, with case 2 showing IgG antibodies to erythrocytes and case 3 showing autoimmune thyroiditis and 2-fold increase of antibody titer to the La/SS-B. None of the patients showed evidence of lupus erythematosus. All 3 patients suffered from multifocal disease with red to purple, non-ulcerated, sometimes painful nodules or plaques involving the face, trunk and extremities. All 3 patients also had B-symptoms and elevated lactate dehydrogenase (LDH) level.

Figures 1-3 show results of the PET/CT primary staging and monitoring of treatment response in the 3 patients, respectively. Primary staging by PET/CT showed multiple foci of increased uptake in the subcutaneous fat of all patients, with the SUVmax ranging from 10.5 to 14.6. Involvement of intra-abdominal fat with high SUVmax was identified in 2 of the patients; specifically, case 1 showed progression of lymphoma at interim PET, and case 3 showed progression at primary staging.

Initial steroid monotherapy was unsuccessful in case 1. All 3 patients received multi-agent chemotherapy. In cases 1 and 3, the lymphoma was refractory to the therapy; case 1 received the cyclophosphamide, doxorubicine, vincristine and prednisolone (CHOP) regimen and case 3 received the fludarabine, mitoxantrone and cyclophosphamide (FCM) regimen. The gemcitabine, cisplatin and methylprednisolone (GEM-P) regimen was used as first-line therapy for case 2 and as second-line therapy for cases 1 and 3, and led to CMR in all. All 3 of the patients remained in remission at the time of last follow-up (range, 8-29 mo).

**DISCUSSION**

The extent of lymphoid tumors and their associated pathologic characteristics play an important role in the choice of therapeutic algorithm, and quantification of disease burden during the therapy is crucial for decision-making of whether to continue the ongoing treatment regimen or to change it. Despite the fact that FDG PET has been used increasingly for staging and response assessment for different types of lymphomas, the experience of its use in SPTCL is limited[8-14]. Analysis of published data on 7 patients with SPTCL revealed FDG-avid tumors in 71%[8]. Feeney *et al*[11] studied 9 SPTCL patients, all of who were PET-positive, and the average SUVmax was 5.7 (range, 1.5-13.1).

All 3 of our patients showed FDG-avid lesions in the pre-treatment PET, which correlated with a high index of proliferative activity of lymphoid cells. In addition, generalized distribution of subcutaneous fat foci with high SUVmax were identified in the mesenteric fat in 2 of the patients. Involvement of intra-abdominal fat in SPTCL has been described in recent years[15,16]. Our results suggest that PET/CT may therefore be useful in detecting occult extracutaneous involvement in SCPTL. However, the prognostic value of intra-abdominal dissemination of SCPTL is unknown.

To evaluate the effectiveness of chemotherapy, we focused on the FDG PET/CT data in addition to the clinical picture of the cases. In case 1, following 6 cycles of the CHOP regimen, a marked improvement was noted, which manifested as normalization of temperature and LDH level, and a significant reduction in the size and density of the subcutaneous nodules. However, the FDG PET/CT data revealed preservation of previously defined and developing new lesions, which led to a change in the chemotherapy regimen to that of GEM-P. After 6 cycles of the GEM-P chemotherapy regimen, CMR was obtained. In case 2, following 7 cycles of the GEM-P chemotherapy regimen, palpable subcutaneous nodules and elevated LDH was still present but the FDG PET/CT data revealed CMR; as a result, the therapy was discontinued and the risks associated with overtreatment were avoided. In case 3, following 3 cycles of the FCM chemotherapy regimen, an ambivalentpicture was observed, with the disappearance of previously palpable nodes and the emergence of new, fast-growing, subcutaneous nodules. For this last case, the FDG PET/CT data confirmed development of new lesions, with SUVmax of 12.9, and a lack of FDG accumulation in the previous nodules.Three cycles of the GEM-P chemotherapy regimen produced CMR, after which 3 consolidating cycles of GEM-P were added.

Recently, SPTCL was classified as a lymphoid tumor with indolent clinical course[17]. However, in each of our 3 patients, despite the lack of hemophagocytic syndrome, the SPTCL course progressed rapidly. B-symptoms and LDH increase were observed, and the index of proliferative activity of the tumor was about 50%-70%, which is comparable with the proliferative activity of diffuse large B cell lymphoma. Additionally, the PET/CT findings in our cases also suggested aggressive behavior of the tumors.

The GEM-P regimen is accepted as a first-line therapy for treatment of peripheral T cell lymphomas, as well as for lymphoma cases of recurrence or primary resistance[18-20]. Our review of the literature found only a single SPTCL case for which the GEM-P regimen was used as treatment. That patient had been refractory to the CHOP regimen but responded well to GEM-P[21]. Our results suggest that the GEM-P regimen is efficacious for the treatment of SPTCL, including in those patients who are refractory to the CHOP or FCM regimens.

It is possible that SPTCL is an inherently biologically heterogeneous tumor or acquires heterogeneity in the course of tumor progression. It would then be assumed that some SPTCL cases are indolent, have a low index of proliferative activity, with low FDG accumulation, and respond well to immunosuppressive therapy. Alternatively, a rapidly progressive disease course would then be observed in some cases, accompanied by constitutional symptoms and with a high index of proliferative activity and high level of FDG uptake. These more aggressive lymphomas would presumably require multi-agent chemotherapy.

Although there is need for further study, the findings from our 3 cases suggest that FDG PET/CT provides valuable information towards detecting occult lesions in SPTCL and may be useful in disease staging and monitoring of treatment response. Moreover, high FDG uptake on pre-treatment PET could identify patients with aggressive disease and help in choosing first-line therapy.

**COMMENTS**

***Case characteristics***

Three patients (two females, aged 27 and 57 years; one male, aged 22 years) who presented with multiple subcutaneous nodules and accompanying fever.

***Clinical diagnosis***

Panniculitis was the provisional diagnosis.

***Differential diagnosis***

The morphological differential diagnosis included atypical lymphocytic lobular panniculitis, lupus profundus, natural killer (NK) cell and NK-like T cell lymphomas involving subcutis.

***Laboratory diagnosis***

All 3 patients in this study had elevated lactate dehydrogenase level.

***Imaging diagnosis***

Positron emission tomography combined with computed tomography (PET/CT) showed multiple foci of increased uptake of fluorine-18 fluorodeoxyglucose in the subcutaneous fat of all 3 patients; the SUVmax values ranged from 10.5 to 14.6. Involvement of intra-abdominal fat was identified in 2 of the patients.

***Pathological diagnosis***

Subcutaneous panniculitis-like T cell lymphoma (SPTCL).

***Treatment***

Use of the gemcitabine, cisplatin and methylprednisolone regimen as first-line therapy or second-line therapy was followed by achievement of complete metabolic response for all 3 cases.

***Related reports***

SPTCL is a very rare variant of non-Hodgkin’s lymphoma, commonly confused with a non-neoplastic process due to its unusual location; in histological analysis, it can mimic panniculitis.

***Term explanation***

SPTCL is a malignant neoplasm belonging to the non-Hodgkin’s lymphomas.

***Experiences and lessons***

Fluorine-18 fluorodeoxyglucose PET/CT provides valuable information for staging of SPTCL and monitoring of treatment response in patients.

***Peer-review***

The article is well written, clear and concise. The topic and the results are interesting. Methods are sound.

**REFERENCES**

1 **Gonzalez CL**, Medeiros LJ, Braziel RM, Jaffe ES. T-cell lymphoma involving subcutaneous tissue. A clinicopathologic entity commonly associated with hemophagocytic syndrome. *Am J Surg Pathol* 1991; **15**: 17-27 [PMID: 1985499 DOI: 10.1097/00000478-199101000-00002]

2 **Jaffe ES**, Gaulard P, Ralfkiaer E, Cerroni L, Meijer C.J.L.M. Subcutaneous panniculitis-like T-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC, 2008: 294-295

3 **Go RS**, Wester SM. Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: a systematic analysis of 156 patients reported in the literature. *Cancer* 2004; **101**: 1404-1413 [PMID: 15368328 DOI: 10.1002/cncr.20502]

4 **Willemze R**, Jansen PM, Cerroni L, Berti E, Santucci M, Assaf C, Canninga-van Dijk MR, Carlotti A, Geerts ML, Hahtola S, Hummel M, Jeskanen L, Kempf W, Massone C, Ortiz-Romero PL, Paulli M, Petrella T, Ranki A, Peralto JL, Robson A, Senff NJ, Vermeer MH, Wechsler J, Whittaker S, Meijer CJ. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. *Blood* 2008; **111**: 838-845 [PMID: 17934071 DOI: 10.1182/blood-2007-04-087288]

5 **Oschlies I**, Simonitsch-Klupp I, Maldyk J, Konovalov D, Abramov D, Myakova N, Lisfeld J, Attarbaschi A, Kontny U, Woessmann W, Klapper W. Subcutaneous panniculitis-like T-cell lymphoma in children: a detailed clinicopathological description of 11 multifocal cases with a high frequency of haemophagocytic syndrome. *Br J Dermatol* 2015; **172**: 793-797 [PMID: 25456748 DOI: 10.1111/bjd.13440]

6 **van Dongen JJ**, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL, Delabesse E, Davi F, Schuuring E, García-Sanz R, van Krieken JH, Droese J, González D, Bastard C, White HE, Spaargaren M, González M, Parreira A, Smith JL, Morgan GJ, Kneba M, Macintyre EA. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. *Leukemia* 2003; **17**: 2257-2317 [PMID: 14671650 DOI: 10.1038/sj.leu.2403202]

7 **Sandberg Y**, van Gastel-Mol EJ, Verhaaf B, Lam KH, van Dongen JJ, Langerak AW. BIOMED-2 multiplex immunoglobulin/T-cell receptor polymerase chain reaction protocols can reliably replace Southern blot analysis in routine clonality diagnostics. *J Mol Diagn* 2005; **7**: 495-503 [PMID: 16237219 DOI: 10.1016/S1525-1578(10)60580-6]

8 **Barrington SF**, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cheson BD. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. *J Clin Oncol* 2014; **32**: 3048-3058 [PMID: 25113771 DOI: 10.1200/JCO.2013.53.5229]

9 **Kako S**, Izutsu K, Ota Y, Minatani Y, Sugaya M, Momose T, Ohtomo K, Kanda Y, Chiba S, Motokura T, Kurokawa M. FDG-PET in T-cell and NK-cell neoplasms. *Ann Oncol* 2007; **18**: 1685-1690 [PMID: 17716987 DOI: 10.1093/annonc/mdm265]

10 **Rodriguez VR**, Joshi A, Peng F, Rabah RM, Stockmann PT, Savaşan S. Positron emission tomography in subcutaneous panniculitis-like T-cell lymphoma. *Pediatr Blood Cancer* 2009; **52**: 406-408 [PMID: 18985722 DOI: 10.1002/pbc.21805]

11 **Feeney J**, Horwitz S, Gönen M, Schöder H. Characterization of T-cell lymphomas by FDG PET/CT. *AJR Am J Roentgenol* 2010; **195**: 333-340 [PMID: 20651187 DOI: 10.2214/AJR.09.3665]

12 **Babb A**, Zerizer I, Naresh KN, Macdonald D. Subcutaneous panniculitis-like T-cell lymphoma with extracutaneous dissemination demonstrated on FDG PET/CT. *Am J Hematol* 2011; **86**: 375-376 [PMID: 21442643 DOI: 10.1002/ajh.21874]

13 **Uematsu T**, Kasami M. 3T-MRI, elastography, digital mammography, and FDG-PET CT findings of subcutaneous panniculitis-like T-cell lymphoma (SPTCL) of the breast. *Jpn J Radiol* 2012; **30**: 766-771 [PMID: 22872501 DOI: 10.1007/s11604-012-0112-5]

14 **Kim JS**, Jeong YJ, Sohn MH, Jeong HJ, Lim ST, Kim DW, Kwak JY, Yim CY. Usefulness of F-18 FDG PET/CT in subcutaneous panniculitis-like T cell lymphoma: disease extent and treatment response evaluation. *Radiol Oncol* 2012; **46**: 279-283 [PMID: 23412422 DOI: 10.2478/v10019-012-0017-z]

15 **Mitsuhashi K**, Momose M, Masuda A, Tsunemi Y, Motoji T. Positron emission tomography revealed diffuse involvement of the lower legs and occult extracutaneous lesions in subcutaneous panniculitis-like T-cell lymphoma. *Clin Nucl Med* 2013; **38**: 209-211 [PMID: 23354029 DOI: 10.1097/RLU.0b013e31827087ca]

16 **Lester L**, Ewalt M, Warnke R, Kim J. Systemic panniculitis-like T-cell lymphoma with involvement of mesenteric fat and subcutis. *J Cutan Pathol* 2015; **42**: 46-49 [PMID: 25384366 DOI: 10.1111/cup.12436]

17 **Quintanilla-Martinez L**, Jansen PM, Kinney MC, Swerdlow SH, Willemze R. Non-mycosis fungoides cutaneous T-cell lymphomas: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop. *Am J Clin Pathol* 2013; **139**: 491-514 [PMID: 23525618 DOI: 10.1309/AJCP83AOQTMLOJTM]

18 **Ng M**, Waters J, Cunningham D, Chau I, Horwich A, Hill M, Norman AR, Wotherspoon A, Catovsky D. Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. *Br J Cancer* 2005; **92**: 1352-1357 [PMID: 15812553 DOI: 10.1038/sj.bjc.6602514]

19 **Arkenau HT**, Chong G, Cunningham D, Watkins D, Sirohi B, Chau I, Wotherspoon A, Norman A, Horwich A, Matutes E. Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. *Haematologica* 2007; **92**: 271-272 [PMID: 17296587 DOI: 10.3324/haematol.10737]

20 **Yim KL**, Ashley S. Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) combination treatment for non-Hodgkin T cell lymphoma. *Med Oncol* 2012; **29**: 3535-3539 [PMID: 22825684 DOI: 10.1007/s12032-012-0309-6]

21 **Velez NF**, Ishizawar RC, Dellaripa PF, Saavedra AP, Laga AC, Murphy GF, Fisher DC, Kupper TS, Vleugels RA. Full facial edema: a novel presentation of subcutaneous panniculitis-like T-cell lymphoma. *J Clin Oncol* 2012; **30**: e233-e236 [PMID: 22826278 DOI: 10.1200/JCO.2011.40.7684]

**P-Reviewer:** Mehdi I, Mocellin S **S-Editor:** Ji FF **L-Editor: E-Editor:**



**Figure 1 Case 1.** A: Before treatment, showing multiple confluent pathological foci of hypermetabolic activity in subcutaneous fat (the largest are indicated by arrows on the whole-body image) and pathological foci in the breasts (in transverse sections); B: After 6 cycles of the CHOP regimen, showing no changes in the follow-up examinations, with conservation of previously defined lesions and development of new ones in the subcutaneous tissue (indicated by arrows on the whole-body image) and pathological focus of hypermetabolic activity which had developed in the mesentery of the descending colon (indicated by circles, on the whole-body image as well); C: After 6 cycles of the GEM-P chemotherapy regimen, showing marked improvement, as indicated by resorption of all previously defined foci. CHOP: Cyclophosphamide, doxorubicine, vincristine and prednisolone; GEM-P: Gemcitabine, cisplatin and methylprednisolone.



**Figure 2 Case 2.** A: Before treatment, showing multiple separate and confluent pathological foci of fluorine-18 fluorodeoxyglucose uptake in local dense areas of subcutaneous fat (the largest are indicated by arrows on the whole-body image); B: After 7 cycles of the GEM-P chemotherapy regimen, showing preservation of metabolically inactive areas of consolidation of subcutaneous fat. GEM-P: Gemcitabine, cisplatin and methylprednisolone.



**Figure 3 Case 3.** A: Before treatment, showing multiple pathological foci of hypermetabolic activity in local dense areas of subcutaneous fat (the largest are indicated by arrows, on the whole-body image as well) and pathological foci of fluorine-18 fluorodeoxyglucose uptake in the epiploon in the left mesogastric area (indicated by circles, on the whole-body image as well); B: After 3 cycles of FCM, showing resorption of all previously defined foci (including those in the greater omentum) but development of new ones in the subcutaneous tissue; C: After 3 cycles of GEM-P, showing marked improvement that was indicated by resorption of all previously defined foci. FCM: Fludarabine, mitoxantrone and cyclophosphamide; GEM-P: Gemcitabine, cisplatin and methylprednisolone.

**Table 1 Clinical features of the 3 cases of subcutaneous panniculitis like T cell lymphoma**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Case | Age in years/sex | Localization | Autoimmune disorders | B-symptoms | LDH, IU/mL1 | SUVmax | Chemotherapy | Outcome, FU in mo |
| 1 | 27/F | Head, neck, upper extremities, chest, breasts, mesocolon  | - | + | 1.165 | 14.6 | PD→6 × CHOP→6 × GEM-P | CR, 29 |
| 2 | 22/M | Right cheek, upper and lower extremities, trunk | Positive direct Coombs test | + | 1.741 | 10.5 | 7 × GEM-P | CR, 26 |
| 3 | 53/F | Head, trunk, upper and lower extremities, epiploon in the left mesogastric area | Autoimmune thyroiditis, 2-fold increase of anti-La/SS-B level | + | 274 | 13.8 | 3 × FCM→6 × GEM-P | CR, 8  |

1Normal range, < 225 IU/mL. CHOP: Cyclophosphamide, doxorubicine, vincristine and prednisolone; CR: Complete response; FCM: Fludarabine, mitoxantrone and cyclophosphamide; FU: Follow-up; GEM-P: Gemcitabine, cisplatin and methylprednisolone; PD: Prednisone; F: Female; M: Male.